Lux Biosciences, Rutgers enter agreement

Lux Biosciences Inc., a privately held biotechnology company specializing in ophthalmic diseases, announced it has entered into an exclusive license agreement with Rutgers, The State University of New Jersey, to access its polyarylate patent estate.

Lux expects to work in partnership with Rutgers to leverage the assets for the treatment of eye diseases affecting the ocular surface or the back of the eye. Potential therapeutic benefits include sustained therapeutic drug levels at or near the site of the disease, resulting potentially in superior efficacy, while limiting systemic exposure to the drug thus potentially minimizing side effects. Financial terms were not disclosed.